Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Caspases

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin.

Neurology·2014

Same author

Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein.

Neuro-degenerative diseases·2012

Same author

Regulation of α-secretase ADAM10 expression and activity.

Experimental brain research·2011

Same author

The Role of the anti-amyloidogenic secretase ADAM10 in shedding the APP-like proteins.

Current Alzheimer research·2011

Same author

Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2011

Same author

The close link between retinoid signalling and the α-secretase ADAM10 and its potential for treating Alzheimer's disease (commentary on Jarvis et al.).

The European journal of neuroscience·2010

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Alpha-secretase as a therapeutic target.

Falk Fahrenholz¹

¹Institute of Biochemistry, University of Mainz, Becherweg 30, 55099, Mainz, Germany. bio.chemie@uni-mainz.de

Current Alzheimer Research

|October 3, 2007

Summary

Increasing alpha-secretase activity, such as ADAM10, may treat Alzheimer

Area of Science:

Neuroscience
Molecular Biology
Biochemistry

Background:

Alzheimer disease (AD) is linked to amyloid precursor protein (APP) processing.
The non-amyloidogenic pathway, involving alpha-secretase, prevents amyloid-beta peptide formation.
Alpha-secretase cleavage releases neuroprotective extracellular domains.

Purpose of the Study:

To identify strategies for increasing alpha-secretase activity for AD treatment.
To investigate the regulation of the alpha-secretase ADAM10.
To explore G protein-coupled receptors (GPCRs) as therapeutic targets.

Main Methods:

Analysis of the human ADAM10 promoter.
Treatment of neuroblastoma cell lines with retinoic acid (RA).
Investigation of PAC1 receptor activation by PACAP.

More Related Videos

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Related Experiment Videos

Last Updated: Jul 11, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Main Results:

Retinoic acid upregulates ADAM10, APP, and APLP2 expression and secretion.
Activation of the PAC1 receptor by PACAP enhances alpha-secretase pathway activity.
ADAM10 acts as the primary alpha-secretase, preventing amyloid plaques in AD models.

Conclusions:

Modulating signaling pathways, like RA and PACAP/PAC1, can increase alpha-secretase activity.
Targeting alpha-secretase offers a promising therapeutic strategy for Alzheimer disease.
Enhanced alpha-secretase function holds potential for neuroprotection and preventing AD pathology.